

6. Literaturverzeichnis

Aklillu E, O. M., Hidestrand M et al. (2002). "Functional analysis of six different polymorphic CYP 1B1 enzyme variants found in ethopian population." *Mol Pharmacol.* 2002 Mar;61(3): 586-94.

Bazzano LA, H. J., Muntner P, Vupputuri S, Whelton PK (2003). "Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United states." *Ann Int Medicine* 138(11): 145.

Bejjani BA, L. R., Tomey KF et al. (1998). "Mutations in CYP 1B1, the gene for Cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi arabia." *Am J Hum Gent.* 62: 325-333.

Benowitz NL (1997). "The role of nicotine in smoking related Cardiovascular disease." *Preventive Medicine* 26: 412-417.

Bertolini S, P. L., DiScala L et al. (2004). "Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia." *Atherosclerosis* 174(1): 57-65.

Busch CP, H. L. (2001). "Genetic determinants of type 2 diabetes mellitus." *Clin Genet.* 60(4): 243-54.

Cenarro A, A. M., Castillo S et al (2003). "A common variant in the ABCA1 gene is asociated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia." *J Med Gent.* 40(3): 163-8.

Cho YM, R. M., Moore JH et al. (2004). "Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus." *Diabetologia* 47(3): 549-54.

Cholerton S, A. A., McCracken N et al. (1994). "Poor metabolizers of nicotine and CYP2D6 polymorphism." *Lancet* 343(8888): 62-3.

Connell JM, F. R., MacKenzie SM et al. (2004). "The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation." *Mol Cell Endocrinol* 217(1-2): 243-7.

Curfs DM, K. A., Pachen DM et al. (2005). "Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties." *FASEB J* 10: 1290-2.

Doevendans PA, J. W., Spiering W, Defesche JC, Kastelein JJ (2001). "Molecular genetics and gene expression in atherosclerosis." *Int J Cardiol.* 80(2-3): 161-72.

Dubey RK, G. D., Zacharia LC, Brachiesi F, Imthum B, Jackson EK (2003). "CYP450- and COMT-Derived estradiol metabolites inhibit activity of human coronary artery SMCs." *Hypertension* 41: 807-813.

Elbein SC (2000). "Genetics of type 2 diabetes: an overview for the millenium." *Diabetes Technol Ther.* 2(3): 391-400.

Evans A, T. H., Hense HW, Ferrario M, Sans S, Kuulasmaa K (2001). "Trends in coronary risk factors in the WHO MONICA project." *Int. Journ.of Epidemiol.* 30: 35-40.

Forth W, H. D., Rummel W (1996). *Elimination von Fremdstoffen durch Stoffwechsel.*

Graham-Lorence S, P. J. (1996). "P450s: Structural similarities and functional differences." *The FASEB Journal* 10: 206-14.

Guttmacher AE, C. F. (2003). "Welcome to the genomic era." *N Engl J Med.* 349(10): 996-8.

Hanna IH, D. S., Roodi N, Guengerich FP, Parl FF (2000). "Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity." *Cancer Res.* 60(13): 3440-4.

Hansson GK (1999). "Inflammation and immune response in atherosclerosis." *Curr Atheroscler Rep.* 1(2): 150-5.

Hegele RA (1997). "The genetic basis of atherosclerosis." *Int J Clin Lab Res* 27(1): 2-13.

Hung RJ, B. P., Brennan P et al. (2004). "GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population." *Int J Cancer* 110(4): 598-604.

Inoue K, A. T., Shimada T (2000). "Ethnic related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations." 30 3(285-95).

Irizar A, B. C., Flatt PR, Ioannides C (1995). "Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rat." *Eur J Pharmacol.* 293(4): 385-93.

Irizar A, I. C. (1998). "Marked inhibition of hepatic cytochrome P450 activity in cholesterol-induced atherosclerosis in rabbits." *Toxicology* 126(3): 179-93.

Iwai N, T. N., Yasui N, Kokubo Y et al. (2004). "Genetic analysis of 22 candidate genes for hypertension in the Japanese population." *J Hypertension* 22(6): 1119-26.

Iwano S, N. M., Saito T, Asanuma F, Kamataki T (2005). "A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons." *Biochem Biophys Res Commun* 16,335(1): 220-6.

Izawa H, Y. Y., Okada T et al. (2004). "Prediction of genetic risk for hypertension." *J Cardiol* 43(2): 92-3.

Jeunemaitre X, S. F., Kotelevtsev YV et al. (1992). "Molecular basis of human hypertension: role of angiotensinogen." *Cell*. 1992 71(1): 169-80.

Kannel WB (1976). "The Framingham Study." *Br Med Journal* 2(6046): 1255.

Ko YK, A. J., Harth V et al. (2001). "Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue." *Cancer Res*. 61(11): 4398-404.

Kocabas NA, S. S., Cholerton S, Daly AK, Karakaya AE (2002). "Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a turkish population." *Arch Toxicol*. 76(11): 643-9.

Kondraganti SR, F.-S. P., Gonzalez FJ, Ramos KS, Jiang W, Moorthy B (2003). "Polycyclic aromatic hydrocarbon-inducible DNA adducts: evidence by ³²P-postlabeling and use of knockout mice for Ah receptor-independent mechanisms of metabolic activation in vivo." *Int J Cancer* 103(1): 5-11.

Li R, B. E., Olshan AF et al. (2000). "Glutathione-S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease." *Atherosclerosis* 149(2): 451-62.

Manning RD jr, M. S., Tian N (2003). "Renal and vascular oxidative stress and salt-sensitivity of artery pressure." *Acta Physiol Scand* 179(3): 243-50.

Masseti S, B. N., Manfredi S et al. (2003). "Interactive effect of the glutathione S-transferase genes and cigarette smoking on occurrence and severity of coronary artery risk." *J Mol Med*. 81(8): 488-94.

McIntyre EA, W. M. (2002). "Genetics of type 2 diabetes and insulin resistance: knowledge from human studies." *Clin Endocrinol (Oxf)* 57(3): 303-11.

McLellan RA, O. M., Hidestrand M et al. (2000). "Characterization and functional analysis of two common human cytochrome P450 1B1 variants." *Archives of Biochemistry and Biophysics* 378(1): 175-181.

Mugge A, B. R., Boger RH et al (1994). "Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits." *J Cardiovasc Pharmacol.* 24(6): 994-8.

Munzel T, H. T., Harrison DG (1997). "The physiology and pathophysiology of the nitric oxide/superoxide system." *Herz* 22(3): 158-72.

Nabel EG, M. (2003). "Cardiovascular disease." *N Engl J Med* Jul3(349 (1)): 60-72.

Nebert DW (1990). "Growth signal pathways." *Nature* 347: 709-10.

Nebert DW (1997). "Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?" *Am. J. Genet.* 60: 265-271.

Ono K, I. Y., Mannami T et al. (2003). "Epidemiological evidence of an association between SLC6A2 gene polymorphism and hypertension." *Hypertension Res.* 26(9): 685-9.

Oscarson M, G. H., Rautio A et al. (1998). "Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase." *FEBS Letters* 438: 201-205.

Penckofer S, S. D., Florczak K (2002). "Oxidative stress and cardiovascular disease in type 2 diabetes and the role of antioxidants and pro-oxidants." *J Cardiovasc. Nurs.* 16(2): 68-85.

Pucci L, L. D., Chirulli V et al. (2003). "Cytochrome P450 2J2 polymorphism in healthy Caucasians are those with diabetes mellitus." *Am J Pharmacogenetics* 3(5): 355-8.

Raza H, A. I., John A, Sharma AK (2000). "Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocin-induced diabetic rats fed with *Momordica charantia* fruit extract." *J Biochem Mol Toxicol.* . 14(3): 131-9.

Ross JS, S. N., Donovan MJ, Breitbart RE, Ginsburg GS (2001). "Atherosclerosis: a cancer of the blood vessels?" *Am J Clin Pathol* Dec 116, Suppl: 97-107.

Rothman N, S. P., Poirier MC, Harrington AM, Ford DP, Strickland PT (1995). "The impact of glutathione s-transferase M1 and cytochrome P450 1A1 genotypes on white-blood-cell polycyclic aromatic hydrocarbon-DNA adduct levels in humans." *Mol Carcinog.* 14(1): 63-8.

Saintot M, M. C., Hautefeuille A, Gerber M (2004). "Interaction between genetic polymorphism of cytochrome P450 1B1 and environmental pollutants in breast cancer risk." *Eur J Cancer Prrev.* 13(1): 83-6.

Salama SA, A. W., Hunter GC et al. (2002). "Polymorphic metabolizing genes and susceptibility to atherosclerosis among cigarette smokers." *Environ Mol Mutagen.* 40(3): 153-60.

Sanke T (2002). "Diagnostic use of gene polymorphism for type 2 diabetes." *Rinsho Byori* 50(9): 871-6.

Sarfarazi M, A. A., Hossain A et al. (1995). "Assignment of a locus (GLC3A) for primary congenital glaucoma (Buphthalmos) to 2p21 and evidence for genetic heterogeneity." *Genomics* 30: 171-177.

Savas Ü, C. C., Jefcoate CR (1997). "Biological oxidation and P450 Reactions." *Archives of Biochemistry and Biophysics* 347(2): 181-92.

Schrenk D, B. D., Morike K, Bock KW, Eichelbaum M (1998). "A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers." *Eur J Clin Pharmacol* 53(5): 361-7.

Schulz E, A. E., Keaney JF Jr. (2004). "Oxidative stress, antioxidants, and endothelial function." *Curr Med Chem.* 11(9): 1093-104.

Shimada T, W. J., Kawajiri K et al. (1999). "Catalytic properties of polymorphic human cytochrome P450 1B1 variants." *Carcinogenesis* 20(8): 1607-1614.

Shinozaki S, Y. Z., Iijima S, Asaka A (1996). "Association of cytochrome P-450 1A1 (CYP1A1) gene polymorphisms to smoking status and hematological findings." *Nippon Koshu Eisei Zasshi* 43(4): 308-14.

Stoilov I, A. A., Alozie I et al. (1998). "Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of Cytochrome P450 1B1." *Am J Hum Genet.* 62: 573-584.

Stoilov I, A. A., Sarfarazi M (1997). "Identification of three different truncating mutations in cytochrome P4501B1 (CYP 1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21." *Human Molecular Genetics* 6(4): 641-647.

Sutter TR, G. K., Dold KM, Greenlee WF (1991). "Targets for dioxin: genes for plasminogen activator inhibitor-2 and interleukin-1 beta." *Science* 254: 415-18.

Sutter TR, T. Y., Hayes CL et al. (1994). "Complete cDNA Sequence of a human dioxin-inducible mRNA identifies a new gene Subfamily of Cytochrome P450 that maps to Chromosome 2." *The Journal of Biological Chemistry* 269(May 6): 13092-13099.

Tamer L, E. B., Camsari A et al. (2004). "Glutathione S-transferase gene polymorphism as a susceptibility factor in smoking-related coronary artery disease." *Basic Res. Cardiol.* 99(3): 223-9.

Tang YM, G. B., Chen GF et al. (2000). "Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls." *Pharmacogenetics.* 10(9): 761-6.

Tang YM, W. Y.-Y., Stewart J et al. (1996). "Isolation and characterization of the Human Cytochrome P450 CYP1B1 Gene." *The Journal of Biological Chemistry* 271(Nov 8): 28324-28330.

Thiery J, T. D. (1998). "Genetische Faktoren der Atheroskleroseentstehung." *Zeitschrift für Kardiologie* 87(10): 777-787.

Toye A, G. D. (2003). "Genetics and functional genomics of type 2 diabetes mellitus." *Genome Biol.* 4(12): 241.

VanSchooten FJ, H. A., Maas LM, et al. (1998). "Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue." *FASEB J.* 12(13): 1409-17.

Varrett M, R. J., Saint-Jore B et al. (1999). "A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32." *Am J Hum Gent.* 64(5): 1378-87.

Wang XL, G. M., Sim AS, Duarte N, Wang J, Wilcken DE (2002). "Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes." *Atherosclerosis* 162(2): 391-7.

Willey JC, C. E., Frampton MW et al. (1997). "Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers." *Am J Respir Cell Mol Biol* 17(1): 114-124.

Yasar U, B. A., Eliasson E et al. (2003). "Allelic variants of cytochrome P450 2C modify risk for acute myocardial infarction." *Pharmacogenetics* 13(12): 715-720.

Zheng W, X. D., Jin F et al. (2000). "Genetic polymorphism of cytochrome P450 1B1 and risk of breast cancer." *Cancer Epidemiol Biomarkers Prev.* 9(2): 147-50.